| 摘要 |
<p>It is described to use of a preparation comprising estrogen being selected from 2.0 to 6.0 mg of 17 beta-estradiol and 0.015 to 0.020 mg of ethinylestradiol and gestagen selected from 0.05 to 0.075 mg of gestodene, 0.075 to 0.125 mg of levonorgestrel, 0.06 to 0.15 mg of desogestrel, 0.06 to 0.15 mg of 3-ketodesogestrel, 0.1 mg of drospirenone to a drospirenone dose equivalent to 0.075 mg of gestodene, 0.1 mg of cyproterone acetate to a cyproterone acetate dose equivalent to 0.075 mg of gestodene, 0.2 to 0.3 mg of norgestimate and more than 0.35 to 0.75 mg of norethisterone for contraception for a woman of fertile age who has not reached the premenopause, by administering the dosage form during 23 or 24 days, starting on day one of the menstrual cycle, followed by 5 or 4 pill-free or placebo pill days, for a total of 28 days in the administration cycle, wherein the individual dosage forms contain a constant amount of estrogen/gestagen throughout the 23 or 24 days; a monophasic combination product for oral contraception.</p> |
